Skip to main content
icon for Hantavirus vaccine in 2026?

Hantavirus vaccine in 2026?

icon for Hantavirus vaccine in 2026?

Hantavirus vaccine in 2026?

6% szansa
Polymarket

$129,605 Wol.

6% szansa
Polymarket

$129,605 Wol.

This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No approved hantavirus vaccine exists for general use in the United States or most Western countries as of mid-2026, driving the 94.5% market-implied probability against availability this year. Vaccine candidates, including mRNA constructs from Moderna and Korea University plus several DNA platforms targeting Gn-Gc glycoproteins, remain in preclinical or Phase 1/2 testing with no Phase 3 trials underway. Standard development timelines, biosafety constraints on virus handling, and limited commercial incentive for a rare rodent-borne pathogen further reduce near-term prospects. A major outbreak triggering emergency authorization or accelerated funding could alter trajectories, though current model consensus and trial data indicate such shifts remain improbable before year-end.

This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".

The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Wolumen
$129,605
Data zakończenia
Dec 31, 2026
Rynek otwarty
May 4, 2026, 10:39 AM ET
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No approved hantavirus vaccine exists for general use in the United States or most Western countries as of mid-2026, driving the 94.5% market-implied probability against availability this year. Vaccine candidates, including mRNA constructs from Moderna and Korea University plus several DNA platforms targeting Gn-Gc glycoproteins, remain in preclinical or Phase 1/2 testing with no Phase 3 trials underway. Standard development timelines, biosafety constraints on virus handling, and limited commercial incentive for a rare rodent-borne pathogen further reduce near-term prospects. A major outbreak triggering emergency authorization or accelerated funding could alter trajectories, though current model consensus and trial data indicate such shifts remain improbable before year-end.

This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".

The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Wolumen
$129,605
Data zakończenia
Dec 31, 2026
Rynek otwarty
May 4, 2026, 10:39 AM ET
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.

Uważaj na linki zewnętrzne.

Często zadawane pytania

"Hantavirus vaccine in 2026?" to rynek prognoz na Polymarket, gdzie traderzy kupują i sprzedają udziały "Tak" lub "Nie" w zależności od tego, czy wierzą, że to wydarzenie nastąpi. Obecne zbiorowe prawdopodobieństwo to 6% na "Yes". Na przykład, jeśli "Tak" kosztuje 6¢, rynek zbiorowo przypisuje 6% szansy na to, że to wydarzenie nastąpi. Te kursy zmieniają się ciągle, gdy traderzy reagują na nowe informacje i wydarzenia. Udziały w poprawnym wyniku można wymienić na $1 za sztukę po rozstrzygnięciu rynku.

Na dzień dzisiejszy "Hantavirus vaccine in 2026?" wygenerował $129.6K łącznego wolumenu od uruchomienia rynku May 4, 2026. Ten poziom aktywności handlowej odzwierciedla silne zaangażowanie społeczności Polymarket i pomaga zapewnić, że bieżące kursy są informowane przez głęboką pulę uczestników rynku. Możesz śledzić ruchy cen na żywo i handlować na dowolny wynik bezpośrednio na tej stronie.

Aby handlować na "Hantavirus vaccine in 2026?", wybierz, czy uważasz, że odpowiedź to "Tak" czy "Nie". Każda strona ma bieżącą cenę odzwierciedlającą implikowane prawdopodobieństwo rynku. Wpisz kwotę i kliknij "Handluj". Jeśli kupisz udziały "Tak" i wynik okaże się "Tak", każdy udział wypłaci $1. Jeśli okaże się "Nie", Twoje udziały "Tak" wypłacą $0. Możesz też sprzedać swoje udziały w dowolnym momencie przed rozstrzygnięciem, jeśli chcesz zrealizować zysk lub ograniczyć stratę.

Obecne prawdopodobieństwo dla "Hantavirus vaccine in 2026?" to 6% na "Yes". Oznacza to, że społeczność Polymarket uważa, że istnieje 6% szansy na to, że to wydarzenie nastąpi. Te kursy aktualizują się w czasie rzeczywistym na podstawie rzeczywistych transakcji, dostarczając ciągle aktualizowany sygnał tego, czego rynek oczekuje.

Zasady rozstrzygania "Hantavirus vaccine in 2026?" określają dokładnie, co musi się wydarzyć, aby każdy wynik został ogłoszony zwycięzcą — w tym oficjalne źródła danych używane do ustalenia wyniku. Możesz przejrzeć pełne kryteria rozstrzygania w sekcji "Zasady" na tej stronie nad komentarzami. Zalecamy dokładne zapoznanie się z zasadami przed handlem, ponieważ określają one precyzyjne warunki, przypadki graniczne i źródła regulujące rozstrzyganie tego rynku.